Pacific Growth Keeps 'Overweight' on Gen-Probe

Adam Chazan says the FDA's timely approval of a new testing device surprised many investors

Pacific Growth keeps its overweight rating on Gen-Probe (GPRO ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.